Artificial Intelligence and Kidney Care | Docwire News
Len Usvyat spoke with Nephrology Times about the use of artificial intelligence and analytics in kidney care.
Related Articles
Popular diet warning as it’s linked to raised levels of ‘bad’ cholesterol
A new study has found that a certain type of diet, which has been previously hailed for its health benefits, could lead to raised levels…
‘Bad’ cholesterol levels could be raised by this weight loss diet
This popular way of eating has been used by those looking to lose weight and control their blood sugar levels, but it could also have…
Water Resources Management | Globalwaters.org
Alignment with the U.S. Global Water Strategy This topic aligns with Strategic Objective 3 in the U.S. Global Water Strategy: Improve Climate-Resilient Conservation and Management…
The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes: a population-based retrospective cohort study – BMC Medicine
Background High levels of high-density lipoprotein cholesterol (HDL-C) are previously considered protective against cardiovascular diseases (CVD), but recent studies suggest an increased risk of adverse…
TCTMD – tctmd.com
TCTMD: the most comprehensive online resource for interventional cardiology and beyond, with news coverage spanning the entire field of cardiovascular disease.
A bottle of wine a week could protect your heart, says study
Here’s how a glass a day could keep heart disease away
Wine may be good for the heart, new study says, but experts aren’t convinced | CNN
Drinking under a glass of wine a day while on Mediterranean diet might help the heart, a new study finds. Experts aren’t so sure.
Wine In Moderation With Mediterranean Diet May Benefit Heart Health
New research suggests that low to moderate wine consumption while adhering to the Mediterranean diet may help lower the risk of heart disease. However, experts…
Vibecotamab Appears Safe for Low-Blast, High Risk MDS and CMML | Docwire News
In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome and chronic myelomonocytic leukemia, vibecotamab appeared well-tolerated.
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | NEJM
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering…
